Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, aged 18-65~* in good health other than major depression for 8 weeks or more~* negative pregnancy test~* able to comply with instructions~* able to provide informed consent~Exclusion Criteria:~* pregnant or lactating~* danger to self or others~* severe kidney or liver disease~* schizophrenia~* allergy to scopolamine or naltrexone~* glaucoma~* Monoamine oxidase (MAO) inhibitor use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- control (Type: PLACEBO_COMPARATOR): Participants will receive placebo medication
- Active (Type: EXPERIMENTAL): participants will receive active medications scopolamine and naltrexone

Based on this trial design, predict the completion outcome and termination type (if applicable).